The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and time to response of [177Lu]Lu-DOTATATE in patients with newly diagnosed advanced grade 2 and grade 3, well-differentiated gastroenteropancreatic neuroendocrine tumors: Sub-analysis of the phase 3 randomized NETTER-2 study.
 
Pamela L. Kunz
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; BMS; HUTCHMED; Ipsen; ITM Isotope Technologies Munich
Research Funding - Advanced Accelerator Applications/Novartis (Inst); RayzeBio (Inst)
 
Diego Ferone
Consulting or Advisory Role - Camurus; Ipsen; Novartis; Pfizer; Recordati
Speakers' Bureau - Novartis; Recordati
Research Funding - Camurus; Pfizer
 
Daniel M. Halperin
Consulting or Advisory Role - Amryt Pharma; Camurus; Chimeric Therapeutics; Crinetics Pharmaceuticals; Harbour BioMed; Ipsen; Isotopen Technologien; Novartis; Progenics; Radiomedix; Tersera
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Genentech/Roche (Inst); Isotopen Technologien (Inst); RayzeBio (Inst); Tarveda Therapeutics (Inst); Thermo Fisher Scientific (Inst)
 
Sten Myrehaug
Consulting or Advisory Role - Ipsen; Novartis
Research Funding - Ipsen
 
Ken Herrmann
Leadership - Pharma15; SOFIE; Theragnostics
Stock and Other Ownership Interests - AdvanCell; Aktis Oncology; Convergent Therapeutics; Pharma15; SOFIE; Theragnostics
Consulting or Advisory Role - Advanced Accelerator Applications; Amgen; AstraZeneca; Bain Capital; Bayer; Boston Scientific; BTG; Debiopharm Group; Fusion Pharmaceuticals; GE Healthcare; Immedica; IPSEN; ITG (Inst); Janssen Oncology; Molecular Partners; Novartis; Radiopharm Theranostics; ROTOP Pharmaka (Inst); Siemens Healthineers; Telix Pharmaceuticals
 
Marianne Pavel
Honoraria - Advanced Accelerator Applications; Boehringer Ingelheim; IPSEN; Lilly; MSD; Novartis; Recordati; Riemser
Consulting or Advisory Role - Advanced Accelerator Applications; Crinetics Pharmaceuticals (Inst); IPSEN; Isotopen Technologien; Novartis
 
Beth Chasen
No Relationships to Disclose
 
Jaume Capdevila
Consulting or Advisory Role - Advanced Accelerator Applications; Bayer; Eisai; Esteve; Exelixis; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sanofi
Speakers' Bureau - Bayer; Eisai; Esteve; Hutchison MediPharma; Ipsen; Isotopen Technologien; Lilly; Merck Serono; Novartis; Pfizer; Sanofi
Research Funding - Advanced Accelerator Applications (Inst); AstraZeneca (Inst); Bayer (Inst); Eisai (Inst); Gilead Sciences (Inst); Ipsen (Inst); Ipsen (Inst); ITM Solucin (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Eisai; Gilead Sciences; Ipsen; Pfizer
 
Salvatore Tafuto
Consulting or Advisory Role - Boehringer Ingelheim; Deciphera; Ipsen; Novartis
Research Funding - Ipsen; Novartis
 
Do-Youn Oh
Consulting or Advisory Role - Arcus Biosciences; ASLAN Pharmaceuticals; AstraZeneca; Basilea; Bayer; BeiGene; Celgene; Genentech/Roche; Halozyme; IQVIA; Merck Serono; MSD Oncology; Novartis; Taiho Pharmaceutical; Turning Point Therapeutics; Yuhan; Zymeworks
Research Funding - Array BioPharma; AstraZeneca; BeiGene; Handok; Lilly; MSD; Novartis; SERVIER
 
Changhoon Yoo
Honoraria - AstraZeneca; Bayer; Boryung Pharmaceuticals; Bristol-Myers Squibb; Celgene; Eisai; Ipsen; MSD Oncology; Novartis; Roche/Genentech; SERVIER
Research Funding - AstraZeneca; Bayer; Boryung Pharmaceuticals; CKD pharm; Eisai; Lunit; SERVIER
 
Stephen Falk
Stock and Other Ownership Interests - GlaxoSmithKline; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb
Speakers' Bureau - Amgen; Merck Serono; SERVIER
Research Funding - AstraZeneca (Inst); Gilead Sciences (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Celgene
Other Relationship - SERVIER
 
Thorvardur Ragnar Halfdanarson
Consulting or Advisory Role - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); Ipsen (Inst); ITM Isotope Technologies Munich (Inst); Tersera; Viewpoint Molecular Targeting (Inst)
Research Funding - Advanced Accelerator Applications (Inst); Camurus (Inst); Crinetics Pharmaceuticals (Inst); ITM Isotope Technologies Munich (Inst); Novartis (Inst); Perspective Therapeutics (Inst); Thermo Fisher Scientific (Inst); Turnstone Bio (Inst)
(OPTIONAL) Uncompensated Relationships - North American Neuroendocrine Tumor Society
 
Ilya Folitar
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Travel, Accommodations, Expenses - Novartis
 
Yufen Zhang
Employment - Novartis
 
Wouter W. de Herder
Consulting or Advisory Role - Advanced Accelerator Applications; Ipsen
Speakers' Bureau - Advanced Accelerator Applications; Ipsen
 
Simron Singh
Employment - Sanofi (I)
Honoraria - Advanced Accelerator Applications/Novartis; IPSEN
Consulting or Advisory Role - Advanced Accelerator Applications/Novartis; Advanz Pharma; Camurus; IPSEN
Research Funding - Novartis (Inst)